Gilead Sciences Inc (GILD)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$121.10

Buy

$121.22

arrow-up$1.375 (+1.15%)

Prices updated at 16 Dec 2025, 14:48 EST

Prices minimum 15 mins delay

Prices in USD

Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

NASDAQ

-0.35%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2023	2024
	27,116m	28,754m
	20,618m	22,503m
	8,810m	10,505m
	32.49	36.53
	5,665m	480m
	10,496m	4,434m
Sales, General and administrative	6,090m	6,091m
Interest expenses	944m	977m
Provision for income taxes	1,247m	211m
Operating expenses	11,808m	11,998m
Income before taxes	6,859m	690m
Net income available to common shareholders	5,665m	480m
	4.54	0.38
Net interest income	-568m	-696m
Advertising and promotion	-	-
Net investment income, net	-	-
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	4.5	0.38
Free cash flow per share	6.2301	7.5508
Book value/share	17.9071	14.8235
Debt equity ratio	1.015591	1.287946

Balance sheet

Year chevron-l-regular chevron-r-regular	2023	2024
Current assets	16,085m	19,173m
Current liabilities	11,280m	12,004m
Total capital	46,022m	44,226m
Total debt	24,987m	26,711m
Total equity	22,833m	19,330m
Total non current liabilities	-	-
Loans	23,189m	24,896m
Total assets	62,125m	58,995m
Total liabilities	-	-
Cash and cash equivalents	6,085m	9,991m
Common stock	1,246m	1,246m

Cash flow

Year chevron-l-regular chevron-r-regular	2023	2024
Cash at beginning of period	5,412m	6,085m
Cash dividends paid	-3,809m	-3,918m
	7,421m	10,305m
Investments (gains) losses	-2,265m	-3,449m
	6,085m	9,991m
Net income	-	-
	8,006m	10,828m
	-585m	-523m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.